Current Medical Research and Opinion · Nov 20, 2026
Long-term metformin therapy and risk of anemia in type 2 diabetes
By Abdalla MAE, Al-kuraishy HM, Saad AY et al.
Metformin is the cornerstone therapy for type 2 diabetes (T2D) and is prescribed long term to large patient populations, making its potential hematological effects clinically relevant. Particular attention has focused on metformin-associated vitamin B12 deficiency and its possible contribution to anemia. Accumulating evidence demonstrates that metformin reduces serum vitamin B12 concentrations and increases the risk of biochemical deficiency, particularly with higher doses and prolonged treatment. However, its overall effects on hemoglobin levels and anemia risk remain modest and variable across clinical populations. Importantly, anemia in patients with T2D is multifactorial and may result from chronic kidney disease, iron deficiency, systemic inflammation, blood loss, or other nutritional deficiencies, complicating the identification of metformin's independent contribution. Although vitamin B12 depletion represents a plausible mechanism linking metformin exposure to hematological abnormalities, additional metabolic and clinical factors may influence erythropoiesis and hemoglobin homeostasis. Furthermore, longer treatment duration and greater cumulative exposure may increase the likelihood of vitamin B12 deficiency, highlighting the importance of appropriate clinical surveillance. Accordingly, this narrative review critically examines the relationship between long-term metformin therapy and anemia risk in patients with T2D, with particular emphasis on vitamin B12 depletion, alterations in hemoglobin levels, and potential underlying mechanisms. It further explores the influence of treatment duration and dosage, identifies patient-related and disease-associated risk factors, and evaluates evidence-based approaches to early detection, prevention, monitoring, and management of hematological complications. Understanding these associations may help optimize long-term metformin therapy while minimizing preventable hematological adverse effects without compromising its established metabolic benefits.
doi.org/10.1080/03007995.2026.2763874PubMed 43063022Interventions